A study at two US medical centers found that patients with brain metastases from gastrointestinal (GI) cancers had significantly worse overall survival and intracranial progression-free survival (PFS) ...

Early-onset gastrointestinal (GI) cancers are climbing among those younger than 50 years, in the US and globally. Although colorectal cancer accounts for approximately half of such cases, rates are ...

Rates of early onset pancreatic, appendix, and gastric malignancies are also increasing among those under 50. Fact checked by Nick Blackmer Colorectal cancer has gained attention for rising rates ...

Young people appear to be increasingly vulnerable to gastrointestinal cancers, but researchers aren’t entirely sure what is driving the surge in disease. In a new study out this week, scientists led ...

Second primary malignancies (SPMs) arise when a patient with a history of one gastrointestinal (GI) cancer develops a new, distinct cancer in the GI tract or elsewhere. Advances in early detection and ...

Healthy dietary patterns reduce GI cancer risk and mortality, while unhealthy patterns increase risk, particularly for colorectal and liver cancers. PCA-derived dietary patterns show stronger ...

Tiago Biachi, MD, PhD, highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, ...

The liver is an extremely sensitive organ. It filters blood, eliminates toxins and creates bile to digest food; without a functioning liver, a person will die. Its sensitive nature, however, makes it ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

Gastrointestinal cancer cases are expected to double worldwide by 2050, according to a multi-institutional study co-led by Cedars-Sinai. The projections, based on 2022 data and published in the ...

Key Points Interested in Seres Therapeutics, Inc.? Here are five stocks we like better. SER-155 showed an 80% response rate ...